Nrf2 in health and disease: Current and future clinical implications

Clinical Science

Volumn 129, Issue 12, 2015, Pages 989-999

  Al Sawaf, Othman ^a   Clarner, Tim ^a   Fragoulis, Athanassios ^a   Kan, Yuet Wai ^b   Pufe, Thomas ^a   Streetz, Konrad ^a   Wruck, Christoph Jan ^a  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cardiovascular disease; Chronic kidney disease; Clinical trials; Multiple sclerosis; Nrf2; Oxidative stress

Indexed keywords

ANTIOXIDANT; TRANSCRIPTION FACTOR NRF2; NFE2L2 PROTEIN, HUMAN;

ALCOHOL LIVER DISEASE; ALZHEIMER DISEASE; ANTIOXIDANT ACTIVITY; APOPTOSIS; BASIC RESEARCH; CARDIOVASCULAR DISEASE; CELL PROTECTION; CHRONIC DISEASE; CHRONIC INFLAMMATION; CHRONIC KIDNEY DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL PRACTICE; DEGENERATIVE DISEASE; DIABETIC NEPHROPATHY; DISEASE COURSE; DRUG RESISTANCE; FOCAL GLOMERULOSCLEROSIS; GAIN OF FUNCTION MUTATION; HUMAN; KIDNEY FIBROSIS; KIDNEY INJURY; LIVER CELL CARCINOMA; LUNG EMPHYSEMA; MULTIPLE SCLEROSIS; OXIDATIVE STRESS; PARKINSON DISEASE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; UPREGULATION; VIRUS HEPATITIS; AGONISTS; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG DEVELOPMENT; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; KIDNEY DISEASES; LIVER DISEASES; LUNG DISEASES; METABOLISM; MOLECULARLY TARGETED THERAPY; NEURODEGENERATIVE DISEASES; SIGNAL TRANSDUCTION;

ANIMALS; ANTIOXIDANTS; DRUG DISCOVERY; GENE EXPRESSION REGULATION; HUMANS; KIDNEY DISEASES; LIVER DISEASES; LUNG DISEASES; MOLECULAR TARGETED THERAPY; NEURODEGENERATIVE DISEASES; NF-E2-RELATED FACTOR 2; OXIDATIVE STRESS; SIGNAL TRANSDUCTION;

EID: 84952009251     PISSN: 01435221     EISSN: 14708736     Source Type: Journal    
DOI: 10.1042/CS20150436     Document Type: Review

References (109)

1. Lee, J.M., Li, J., Johnson, D.A., Stein, T.D., Kraft, A.D., Calkins, M.J., Jakel, R.J. and Johnson, J.A. (2005) Nrf2, a multi-organ protector? FASEB J. 19, 1061-1066
2. Nguyen, T., Nioi, P. and Pickett, C.B. (2009) The Nrf2-antioxidant response element signaling pathway and its activation by oxidative stress. J. Biol. Chem. 284, 13291-13295
3. Kensler, T.W. and Wakabayashi, N. (2010) Nrf2: friend or foe for chemoprevention? Carcinogenesis 31, 90-99
4. Zhang, D.D. (2006) Mechanistic studies of the Nrf2-Keap1 signaling pathway. Drug Metab. Rev. 38, 769-789
5. Canning, P., Sorrell, F.J. and Bullock, A.N. (2015) Structural basis of KEAP1 interactions with Nrf2. Free Radic. Biol. Med.
6. Ishimura, R., Tanaka, K. and Komatsu, M. (2014) Dissection of the role of p62/Sqstm1 in activation of Nrf2 during xenophagy. FEBS Lett. 588, 822-828
7. Jain, A., Lamark, T., Sjottem, E., Larsen, K.B., Awuh, J.A., Øvervatn, A., McMahon, M., Hayes, J.D. and Johansen, T. (2010) p62/SQSTM1 is a target gene for transcription factor NRF2 and creates a positive feedback loop by inducing antioxidant response element-driven gene transcription. J. Biol. Chem. 285, 22576-22591
8. Rada, P., Rojo, A.I., Chowdhry, S., McMahon, M., Hayes, J.D. and Cuadrado, A. (2011) SCF/β-TrCP promotes glycogen synthase kinase 3-dependent degradation of the Nrf2 transcription factor in a Keap1-independent manner. Mol. Cell. Biol. 31, 1121-1133
9. Jain, A.K. and Jaiswal, A.K. (2007) GSK-3β acts upstream of Fyn kinase in regulation of nuclear export and degradation of NF-E2 related factor 2. J. Biol. Chem. 282, 16502-16510
10. Kweider, N., Fragoulis, A., Rosen, C., Pecks, U., Rath, W., Pufe, T. and Wruck, C.J. (2011) Interplay between vascular endothelial growth factor (VEGF) and nuclear factor erythroid 2-related factor-2 (Nrf2): implications for preeclampsia. J. Biol. Chem. 286, 42863-42872
11. Liby, K.T. and Sporn, M.B. (2012) Synthetic oleanane triterpenoids: multifunctional drugs with a broad range of applications for prevention and treatment of chronic disease. Pharmacol. Rev. 64, 972-1003
12. Yates, M.S., Tauchi, M., Katsuoka, F., Flanders, K.C., Liby, K.T., Honda, T., Gribble, G.W., Johnson, D.A., Johnson, J.A., Burton, N.C. et al. (2007) Pharmacodynamic characterization of chemopreventive triterpenoids as exceptionally potent inducers of Nrf2-regulated genes. Mol. Cancer Ther. 6, 154-162
13. Ahmad, R., Raina, D., Meyer, C., Kharbanda, S. and Kufe, D. (2006) Triterpenoid CDDO-Me blocks the NF-κB pathway by direct inhibition of IKKβ on Cys-179. J. Biol. Chem. 281, 35764-35769
14. Mrowietz, U., Altmeyer, P., Bieber, T., Rocken, M., Schopf, R.E. and Sterry, W. (2007) Treatment of psoriasis with fumaric acid esters (Fumaderm). J. Dtsch. Dermatol. Ges. 5, 716-717
15. Lehmann, J.C., Listopad, J.J., Rentzsch, C.U., Igney, F.H., von Bonin, A., Hennekes, H.H., Asadullah, K. and Docke, W.D. (2007) Dimethylfumarate induces immunosuppression via glutathione depletion and subsequent induction of heme oxygenase 1. J. Invest. Dermatol. 127, 835-845
16. Guerrero-Beltran, C.E., Calderon-Oliver, M., Pedraza-Chaverri, J. and Chirino, Y.I. (2012) Protective effect of sulforaphane against oxidative stress: recent advances. Exp. Toxicol. Pathol. 64, 503-508
17. Zhang, Y., Talalay, P., Cho, C.G. and Posner, G.H. (1992) A major inducer of anticarcinogenic protective enzymes from broccoli: isolation and elucidation of structure. Proc. Natl. Acad. Sci. U.S.A. 89, 2399-2403
18. Fragoulis, A., Laufs, J., Müller, S., Soppa, U., Siegl, S., Reiss, L.K., Tohidnezhad, M., Rosen, C., Tenbrock, K., Varoga, D., et al. (2012) Sulforaphane has opposing effects on TNF-alpha stimulated and unstimulated synoviocytes. Arthritis Res. Ther. 14, R220
19. Kallifatidis, G., Rausch, V., Baumann, B., Apel, A., Beckermann, B.M., Groth, A., Mattern, J., Li, Z., Kolb, A., Moldenhauer, G. et al. (2009) Sulforaphane targets pancreatic tumour-initiating cells by NF-κB-induced antiapoptotic signalling. Gut 58, 949-963
20. Ren, D., Villeneuve, N.F., Jiang, T., Wu, T., Lau, A., Toppin, H.A. and Zhang, D.D. (2011) Brusatol enhances the efficacy of chemotherapy by inhibiting the Nrf2-mediated defense mechanism. Proc. Natl. Acad. Sci. U.S.A. 108, 1433-1438
21. Azarenko, O., Okouneva, T., Singletary, K.W., Jordan, M.A. and Wilson, L. (2008) Suppression of microtubule dynamic instability and turnover in MCF7 breast cancer cells by sulforaphane. Carcinogenesis 29, 2360-2368
22. Murakami, S. and Motohashi, H. (2015) Roles of NRF2 in cell proliferation and differentiation. Free Radic. Biol. Med.
23. Sporn, M.B. and Liby, K.T. (2012) NRF2 and cancer: the good, the bad and the importance of context. Nat. Rev. Cancer 12, 564-571
24. Lau, A., Villeneuve, N.F., Sun, Z., Wong, P.K. and Zhang, D.D. (2008) Dual roles of Nrf2 in cancer. Pharmacol. Res. 58, 262-270
25. No, J.H., Kim, Y.B. and Song, Y.S. (2014) Targeting Nrf2 signaling to combat chemoresistance. J. Cancer Prev. 19, 111-117
26. Arlt, A., Sebens, S., Krebs, S., Geismann, C., Grossmann, M., Kruse, M.L., Schreiber, S. and Schafer, H. (2013) Inhibition of the Nrf2 transcription factor by the alkaloid trigonelline renders pancreatic cancer cells more susceptible to apoptosis through decreased proteasomal gene expression and proteasome activity. Oncogene 32, 4825-4835
27. Ren, D.M., Villeneuve, N.F., Jiang, T., Wu, T.D., Lau, A., Toppin, H.A. and Zhang, D.D. (2011) Brusatol enhances the efficacy of chemotherapy by inhibiting the Nrf2-mediated defense mechanism. Proc. Natl. Acad. Sci. U.S.A. 108, 1433-1438
28. Zhu, R.Z., Wang, Y.J., Zhang, L.Q. and Guo, Q.L. (2012) Oxidative stress and liver disease. Hepatol. Res. 42, 741-749
29. Shin, S.M., Yang, J.H. and Ki, S.H. (2013) Role of the Nrf2-ARE pathway in liver diseases. Oxid. Med. Cell. Longev. 2013, 763257
30. Rehermann, B. and Nascimbeni, M. (2005) Immunology of hepatitis B virus and hepatitis C virus infection. Nat. Rev. Immunol. 5, 215-229
31. Waris, G., Huh, K.W. and Siddiqui, A. (2001) Mitochondrially associated hepatitis B virus X protein constitutively activates transcription factors STAT-3 and NF-κB via oxidative stress. Mol. Cell. Biol. 21, 7721-7730
32. Burdette, D., Olivarez, M. and Waris, G. (2010) Activation of transcription factor Nrf2 by hepatitis C virus induces the cell-survival pathway. J. Gen. Virol. 91, 681-690
33. Hou, W.H., Rossi, L., Shan, Y., Zheng, J.Y., Lambrecht, R.W. and Bonkovsky, H.L. (2009) Iron increases HMOX1 and decreases hepatitis C viral expression in HCV-expressing cells. World J. Gastroenterol. 15, 4499-4510
34. Chartoumpekis, D.V. and Kensler, T.W. (2013) New player on an old field: the keap1/Nrf2 pathway as a target for treatment of type 2 diabetes and metabolic syndrome. Curr. Diabetes Rev. 9, 137-145
35. Endo, H., Niioka, M., Kobayashi, N., Tanaka, M. and Watanabe, T. (2013) Butyrate-producing probiotics reduce nonalcoholic fatty liver disease progression in rats: new insight into the probiotics for the gut-liver axis. PLoS One 8, e63388
36. Wu, D.F. and Cederbaum, A.I. (2009) Oxidative stress and alcoholic liver disease. Semin. Liver Dis. 29, 141-154
37. Copple, I.M., Goldring, C.E., Jenkins, R.E., Chia, A.J.L., Randle, L.E., Hayes, J.D., Kitteringham, N.R. and Park, B.K. (2008) The hepatotoxic metabolite of acetaminophen directly activates the Keap1-Nrf2 cell defense system. Hepatology 48, 1292-1301
38. Oh, C.J., Kim, J.Y., Min, A.K., Park, K.G., Harris, R.A., Kim, H.J. and Lee, I.K. (2012) Sulforaphane attenuates hepatic fibrosis via NF-E2-related factor 2-mediated inhibition of transforming growth factor-β/Smad signaling. Free Radic. Biol. Med. 52, 671-682
39. Shimozono, R., Asaoka, Y., Yoshizawa, Y., Aoki, T., Noda, H., Yamada, M., Kaino, M. and Mochizuki, H. (2013) Nrf2 activators attenuate the progression of nonalcoholic steatohepatitis-related fibrosis in a dietary rat model. Mol. Pharmacol. 84, 62-70
40. Ni, H.M., Woolbright, B.L., Williams, J., Copple, B., Cui, W., Luyendyk, J.P., Jaeschke, H. and Ding, W.X. (2014) Nrf2 promotes the development of fibrosis and tumorigenesis in mice with defective hepatic autophagy. J. Hepatol. 61, 617-625
41. Yoo, N.J., Kim, H.R., Kim, Y.R., An, C.H. and Lee, S.H. (2012) Somatic mutations of the KEAP1 gene in common solid cancers. Histopathology 60, 943-952
42. de Haan, J.B. (2011) Nrf2 activators as attractive therapeutics for diabetic nephropathy. Diabetes 60, 2683-2684
43. Jiang, T., Huang, Z., Lin, Y., Zhang, Z., Fang, D. and Zhang, D.D. (2010) The protective role of Nrf2 in streptozotocin-induced diabetic nephropathy. Diabetes 59, 850-860
44. Chang, J., Ma, J.Z., Zeng, Q., Cechova, S., Gantz, A., Nievergelt, C., O'Connor, D., Lipkowitz, M. and Le, T.H. (2013) Loss of GSTM1, a NRF2 target, is associated with accelerated progression of hypertensive kidney disease in the African American Study of Kidney Disease (AASK). Am. J. Physiol. Renal Physiol. 304, F348-F355
45. Kim, H.J., Sato, T., Rodriguez-Iturbe, B. and Vaziri, N.D. (2011) Role of intrarenal angiotensin system activation, oxidative stress, inflammation, and impaired nuclear factor-erythroid-2-related factor 2 activity in the progression of focal glomerulosclerosis. J. Pharmacol. Exp. Ther. 337, 583-590
46. Oh, C.J., Kim, J.Y., Choi, Y.K., Kim, H.J., Jeong, J.Y., Bae, K.H., Park, K.G. and Lee, I.K. (2012) Dimethylfumarate attenuates renal fibrosis via NF-E2-related factor 2-mediated inhibition of transforming growth factor-β/Smad signaling. PLoS One 7, e45870
47. Yoh, K., Itoh, K., Enomoto, A., Hirayama, A., Yamaguchi, N., Kobayashi, M., Morito, N., Koyama, A., Yamamoto, M. and Takahashi, S. (2001) Nrf2-deficient female mice develop lupus-like autoimmune nephritis. Kidney Int. 60, 1343-1353
48. National Kidney Foundation (2002) K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am. J. Kidney Dis. 39 Suppl. 1, S1-S266
49. Hong, D.S., Kurzrock, R., Supko, J.G., He, X., Naing, A., Wheler, J., Lawrence, D., Eder, J.P., Meyer, C.J., Ferguson, D.A. et al. (2012) A phase I first-in-human trial of bardoxolone methyl in patients with advanced solid tumors and lymphomas. Clin. Cancer Res. 18, 3396-3406
50. Pergola, P.E., Raskin, P., Toto, R.D., Meyer, C.J., Huff, J.W., Grossman, E.B., Krauth, M., Ruiz, S., Audhya, P., Christ-Schmidt, H. et al. (2011) Bardoxolone methyl and kidney function in CKD with type 2 diabetes. N. Engl. J. Med. 365, 327-336
51. de Zeeuw, D., Akizawa, T., Agarwal, R., Audhya, P., Bakrise, G.L., Chin, M., Krauth, M., Heerspink, H.J.L., Meyer, C.J., McMurray, J.J. et al. (2013) Rationale and trial design of Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes: The Occurrence of Renal Events (BEACON). Am. J. Nephrol. 37, 212-222
52. de Zeeuw, D., Akizawa, T., Audhya, P., Bakris, G.L., Chin, M., Christ-Schmidt, H., Goldsberry, A., Houser, M., Krauth, M., Heerspink, H.J.L. et al. (2013) Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. New Engl. J. Med. 369, 2492-2503
53. Chin, M.P., Reisman, S.A., Bakris, G.L., O'Grady, M., Linde, P.G., McCullough, P.A., Packham, D., Vaziri, N.D., Ward, K.W., Warnock, D.G. et al. (2014) Mechanisms contributing to adverse cardiovascular events in patients with type 2 diabetes mellitus and stage 4 chronic kidney disease treated with bardoxolone methyl. Am. J. Nephrol. 39, 499-508
54. B-receptor antagonists on regional kidney blood flow, and responses to intravenous endothelin-1, in anaesthetized rabbits. J. Hypertens. 19, 1789-1799
55. Ge, Y., Bagnall, A., Stricklett, P.K., Strait, K., Webb, D.J., Kotelevtsev, Y. and Kohan, D.E. (2006) Collecting duct-specific knockout of the endothelin B receptor causes hypertension and sodium retention. Am. J. Physiol. Renal Physiol. 291, F1274-F1280
56. Vachiery, J.L. and Davenport, A. (2009) The endothelin system in pulmonary and renal vasculopathy: les liaisons dangereuses. Eur. Respir. Rev. 18, 260-271
57. Chin, M.P., Wrolstad, D., Bakris, G.L., Chertow, G.M., de Zeeuw, D., Goldsberry, A., Linde, P.G., McCullough, P.A., McMurray, J.J., Wittes, J. et al. (2014) Risk factors for heart failure in patients with type 2 diabetes mellitus and stage 4 chronic kidney disease treated with bardoxolone methyl. J. Card. Fail. 20, 953-958
58. Lambers Heerspink, H.J., Chertow, G.M., Akizawa, T., Audhya, P., Bakris, G.L., Goldsberry, A., Krauth, M., Linde, P., McMurray, J.J., Meyer, C.J. et al. (2013) Baseline characteristics in the Bardoxolone methyl EvAluation in patients with Chronic kidney disease and type 2 diabetes mellitus: the Occurrence of renal eveNts (BEACON) trial. Nephrol. Dial. Transplant. 28, 2841-2850
59. Xie, Y.H., Wang, S.W., Zhang, Y., Edvinsson, L. and Xu, C.B. (2013) Nuclear factor-κB-mediated endothelin receptor up-regulation increases renal artery contractility in rats. Basic Clin. Pharmacol. Toxicol. 113, 401-410
60. McCullough, P.A. and Ali, S. (2012) Cardiac and renal function in patients with type 2 diabetes who have chronic kidney disease: potential effects of bardoxolone methyl. Drug Des. Devel. Ther. 6, 141-149
61. Hogg, J.C. and Timens, W. (2009) The pathology of chronic obstructive pulmonary disease. Annu. Rev. Pathol. 4, 435-459
62. Adair-Kirk, T.L., Atkinson, J.J., Griffin, G.L., Watson, M.A., Kelley, D.G., DeMello, D., Senior, R.M. and Betsuyaku, T. (2008) Distal airways in mice exposed to cigarette smoke: Nrf2-regulated genes are increased in Clara cells. Am. J. Respir. Cell Mol. Biol. 39, 400-411
63. Iizuka, T., Ishii, Y., Itoh, K., Kiwamoto, T., Kimura, T., Matsuno, Y., Morishima, Y., Hegab, A.E., Homma, S., Nomura, A. et al. (2005) Nrf2-deficient mice are highly susceptible to cigarette smoke-induced emphysema. Genes Cells 10, 1113-1125
64. Ishii, Y., Itoh, K., Morishima, Y., Kimura, T., Kiwamoto, T., Iizuka, T., Hegab, A.E., Hosoya, T., Nomura, A., Sakamoto, T. et al. (2005) Transcription factor Nrf2 plays a pivotal role in protection against elastase-induced pulmonary inflammation and emphysema. J. Immunol. 175, 6968-6975
65. Walters, D.M., Cho, H.Y. and Kleeberger, S.R. (2008) Oxidative stress and antioxidants in the pathogenesis of pulmonary fibrosis: a potential role for Nrf2. Antioxid. Redox Signal. 10, 321-332
66. Voelkel, N.F., Bogaard, H.J., Al Husseini, A., Farkas, L., Gomez-Arroyo, J. and Natarajan, R. (2013) Antioxidants for the treatment of patients with severe angioproliferative pulmonary hypertension? Antioxid. Redox Signal. 18, 1810-1817
67. Reiss, L.K., Fragoulis, A., Siegl, S., Platen, C., Kan, Y.W., Nautiyal, J., Parker, M., Pufe, T., Uhlig, U., Martin, C. et al. (2014) Interplay between nuclear factor erythroid 2-related factor 2 and amphiregulin during mechanical ventilation. Am. J. Respir. Cell Mol. Biol. 51, 668-677
68. Sun, Z.T., Yang, C.Y., Miao, L.J., Zhang, S.F., Han, X.P., Ren, S.E., Sun, X.Q. and Cao, Y.N. (2015) Effects of mechanical ventilation with different tidal volume on oxidative stress and antioxidant in lung. J. Anesth. 29, 346-351
69. Barrios, R., Shi, Z.Z., Kala, S.V., Wiseman, A.L., Welty, S.E., Kala, G., Bahler, A.A., Ou, C.N. and Lieberman, M.W. (2001) Oxygen-induced pulmonary injury in γ-glutamyl transpeptidase-deficient mice. Lung 179, 319-330
70. Chan, K.M. and Kan, Y.W. (1999) Nrf2 is essential for protection against acute pulmonary injury in mice. Proc. Natl. Acad. Sci. U.S.A. 96, 12731-12736
71. Jean, J.C., Liu, Y., Brown, L.A., Marc, R.E., Klings, E. and Joyce-Brady, M. (2002) γ-Glutamyl transferase deficiency results in lung oxidant stress in normoxia. Am. J. Physiol. Lung Cell. Mol. Physiol. 283, L766-L776
72. Magne, J., Pibarot, P., Sengupta, P.P., Donal, E., Rosenhek, R. and Lancellotti, P. (2015) Pulmonary hypertension in valvular disease: a comprehensive review on pathophysiology to therapy from the HAVEC Group. JACC Cardiovasc. Imaging 8, 83-99
73. Carri, M.T., Valle, C., Bozzo, F. and Cozzolino, M. (2015) Oxidative stress and mitochondrial damage: importance in non-SOD1 ALS. Front. Cell Neurosci. 9, 41
74. Chen, Z. and Zhong, C. (2014) Oxidative stress in Alzheimer's disease. Neurosci. Bull. 30, 271-281
75. Gonsette, R.E. (2008) Neurodegeneration in multiple sclerosis: the role of oxidative stress and excitotoxicity. J. Neurol. Sci. 274, 48-53
76. Nataraj, J., Manivasagam, T., Thenmozhi, A.J. and Essa, M.M. (2015) Lutein protects dopaminergic neurons against MPTP-induced apoptotic death and motor dysfunction by ameliorating mitochondrial disruption and oxidative stress. Nutr. Neurosci.
77. Wang, P., Xie, K., Wang, C. and Bi, J. (2014) Oxidative stress induced by lipid peroxidation is related with inflammation of demyelination and neurodegeneration in multiple sclerosis. Eur. Neurol. 72, 249-254
78. Radi, E., Formichi, P., Battisti, C. and Federico, A. (2014) Apoptosis and oxidative stress in neurodegenerative diseases. J. Alzheimers Dis. 42 Suppl. 3, S125-S152
79. Jazwa, A., Rojo, A.I., Innamorato, N.G., Hesse, M., Fernandez-Ruiz, J. and Cuadrado, A. (2011) Pharmacological targeting of the transcription factor Nrf2 at the basal ganglia provides disease modifying therapy for experimental Parkinsonism. Antioxid. Redox Signal. 14, 2347-2360
80. Kim, H.V., Kim, H.Y., Ehrlich, H.Y., Choi, S.Y., Kim, D.J. and Kim, Y. (2013) Amelioration of Alzheimer's disease by neuroprotective effect of sulforaphane in animal model. Amyloid 20, 7-12
81. Wruck, C.J., Claussen, M., Fuhrmann, G., Romer, L., Schulz, A., Pufe, T., Waetzig, V., Peipp, M., Herdegen, T. and Gotz, M.E. (2007) Luteolin protects rat PC12 and C6 cells against MPP+ induced toxicity via an ERK dependent Keap1-Nrf2-ARE pathway. J. Neural Transm. Suppl. 57-67
82. Wruck, C.J., Gotz, M.E., Herdegen, T., Varoga, D., Brandenburg, L.O. and Pufe, T. (2008) Kavalactones protect neural cells against amyloid β peptide-induced neurotoxicity via extracellular signal-regulated kinase 1/2-dependent nuclear factor erythroid 2-related factor 2 activation. Mol. Pharmacol. 73, 1785-1795
83. Paupe, V., Dassa, E.P., Goncalves, S., Auchère, F., Lönn, M., Holmgren, A. and Rustin, P. (2009) Impaired nuclear Nrf2 translocation undermines the oxidative stress response in Friedreich ataxia. Plos One 4, e4253
84. Pitceathly, R.D.S. and McFarland, R. (2014) Mitochondrial myopathies in adults and children: management and therapy development. Curr. Opin. Neurol. 27, 576-582
85. La Mantia, L., Di Pietrantonj, C., Rovaris, M., Rigon, G., Frau, S., Berardo, F., Gandini, A., Longobardi, A., Weinstock-Guttman, B. and Vaona, A. (2014) Interferons-β versus glatiramer acetate for relapsing-remitting multiple sclerosis. Cochrane Database Syst. Rev. 7, CD009333
86. Gilgun-Sherki, Y., Melamed, E. and Offen, D. (2004) The role of oxidative stress in the pathogenesis of multiple sclerosis: the need for effective antioxidant therapy. J. Neurol. 251, 261-268
87. Lassmann, H., van Horssen, J. and Mahad, D. (2012) Progressive multiple sclerosis: pathology and pathogenesis. Nat. Rev. Neurol. 8, 647-656
88. Cross, A.H. and Naismith, R.T. (2014) Established and novel disease-modifying treatments in multiple sclerosis. J. Intern. Med. 275, 350-363
89. Linker, R.A., Lee, D.H., Ryan, S., van Dam, A.M., Conrad, R., Bista, P., Zeng, W., Hronowsky, X., Buko, A., Chollate, S. et al. (2011) Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway. Brain 134, 678-692
90. Fox, R.J., Miller, D.H., Phillips, J.T., Hutchinson, M., Havrdova, E., Kita, M., Yang, M., Raghupathi, K., Novas, M., Sweetser, M.T. et al. (2012) Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N. Engl. J. Med. 367, 1087-1097
91. Gold, R., Kappos, L., Arnold, D.L., Bar-Or, A., Giovannoni, G., Selmaj, K., Tornatore, C., Sweetser, M.T., Yang, M., Sheikh, S.I. et al. (2012) Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N. Engl. J. Med. 367, 1098-1107
92. Havrdova, E., Hutchinson, M., Kurukulasuriya, N.C., Raghupathi, K., Sweetser, M.T., Dawson, K.T. and Gold, R. (2013) Oral BG-12 (dimethyl fumarate) for relapsing-remitting multiple sclerosis: a review of DEFINE and CONFIRM. Expert Opin. Pharmacother. 14, 2145-2156
93. Taguchi, K., Motohashi, H. and Yamamoto, M. (2011) Molecular mechanisms of the Keap1-Nrf2 pathway in stress response and cancer evolution. Genes Cells 16, 123-140
94. Suzuki, T., Motohashi, H. and Yamamoto, M. (2013) Toward clinical application of the Keap1-Nrf2 pathway. Trends Pharmacol. Sci. 34, 340-346
95. Thimmulappa, R.K., Mai, K.H., Srisuma, S., Kensler, T.W., Yamamoto, M. and Biswal, S. (2002) Identification of Nrf2-regulated genes induced by the chemopreventive agent sulforaphane by oligonucleotide microarray. Cancer Res. 62, 5196-5203
96. Tanito, M., Agbaga, M.P. and Anderson, R.E. (2007) Upregulation of thioredoxin system via Nrf2-antioxidant responsive element pathway in adaptive-retinal neuroprotection in vivo and in vitro. Free Radic. Biol. Med. 42, 1838-1850
97. Harvey, C.J., Thimmulappa, R.K., Singh, A., Blake, D.J., Ling, G., Wakabayashi, N., Fujii, J., Myers, A. and Biswal, S. (2009) Nrf2-regulated glutathione recycling independent of biosynthesis is critical for cell survival during oxidative stress. Free Radic. Biol. Med. 46, 443-453
98. Huang, B.W., Ray, P.D., Iwasaki, K. and Tsuji, Y. (2013) Transcriptional regulation of the human ferritin gene by coordinated regulation of Nrf2 and protein arginine methyltransferases PRMT1 and PRMT4. FASEB J. 27, 3763-3774
99. Nioi, P., McMahon, M., Itohm, K., Yamamoto, M. and Hayes, J.D. (2003) Identification of a novel Nrf2-regulated antioxidant response element (ARE) in the mouse NAD(P)H:quinone oxidoreductase 1 gene: reassessment of the ARE consensus sequence. Biochem. J. 374, 337-348
100. Alam, J., Stewart, D., Touchard, C., Boinapally, S., Choi, A.M. and Cook, J.L. (1999) Nrf2, a Cap'n'Collar transcription factor, regulates induction of the heme oxygenase-1 gene. J. Biol. Chem. 274, 26071-26078
101. Park, E.Y. and Rho, H.M. (2002) The transcriptional activation of the human copper/zinc superoxide dismutase gene by 2, 3, 7, 8-tetrachlorodibenzo-p-dioxin through two different regulator sites, the antioxidant responsive element and xenobiotic responsive element. Mol. Cell. Biochem. 240, 47-55
102. Wakabayashi, N., Shin, S., Slocum, S.L., Agoston, E.S., Wakabayashi, J., Kwak, M.K., Misra, V., Biswal, S., Yamamoto, M. and Kensler, T.W. (2010) Regulation of Notch1 signaling by Nrf2: implications for tissue regeneration. Sci. Signal. 3, ra52
103. Al-Sawaf, O., Fragoulis, A., Rosen, C., Keimes, N., Liehn, E.A., Holzle, F., Kan, Y.W., Pufe, T., Sonmez, T.T. and Wruck, C.J. (2014) Nrf2 augments skeletal muscle regeneration after ischaemia-reperfusion injury. J. Pathol. 234, 538-547
104. Wruck, C.J., Streetz, K., Pavic, G., Gotz, M.E., Tohidnezhad, M., Brandenburg, L.O., Varoga, D., Eickelberg, O., Herdegen, T., Trautwein, C. et al. (2011) Nrf2 induces interleukin-6 (IL-6) expression via an antioxidant response element within the IL-6 promoter. J. Biol. Chem. 286, 4493-4499
105. Furusawa, Y., Uruno, A., Yagishita, Y., Higashi, C. and Yamamoto, M. (2014) Nrf2 induces fibroblast growth factor 21 in diabetic mice. Genes Cells 19, 864-878.
106. Onderdijk, A.J., Balak, D.M., Baerveldt, E.M., Florencia, E.F., Kant, M., Laman, J.D., van IJcken, W.F., Racz, E., de Ridder, D., Thio, H.B. et al. (2014) Regulated genes in psoriatic skin during treatment with fumaric acid esters. Br J Dermatol. 171, 732-741
107. Bomprezzi, R. (2015) Dimethyl fumarate in the treatment of relapsing-remitting multiple sclerosis: an overview. Ther. Adv. Neurol. Disord. 8, 20-30
108. Choi, B.H., Kang, K.S. and Kwak, M.K. (2014) Effect of redox modulating NRF2 activators on chronic kidney disease. Molecules 19, 12727-12759
109. Joyce, N.C. (2012) Proliferative capacity of corneal endothelial cells. Exp. Eye Res. 95, 16-23